Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
May 02 2022 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that it
plans to report its financial results for its fiscal second quarter
ended March 31, 2022 after the U.S. market closes on May 9, 2022.
Enanta management will host a conference call at 4:30 p.m. ET to
discuss these results and provide an update on Enanta’s business,
including its research and development pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial
844-467-7101 in the U.S. or 270-215-9353 for international callers.
A replay of the conference call will be available starting at
approximately 7:30 p.m. ET on May 9, 2022, through 11:59 p.m. ET on
May 16, 2022 by dialing 855-859-2056 from the U.S. or 404-537-3406
for international callers. The passcode for both the live call and
the replay is 7061969. A live audio webcast of the call and replay
can be accessed by visiting the “Events and Presentations” section
on the “Investors” page of Enanta’s website at www.enanta.com.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates currently in development
for the following disease targets: respiratory syncytial virus
(RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is
also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005130/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024